Collaboration With Industry And CMS Are Priorities For FDA’s Gottlieb
This article was originally published in The Gray Sheet
Executive Summary
The pressure of meeting MDUFMA premarket review deadlines has prevented FDA reviewers from having "as much interaction as they would like with companies," according to FDA Deputy Commissioner for Medical & Scientific Affairs Scott Gottlieb, MD